News

Abuse Deterrent Coalition Sends Letter to FDA Commissioner, Scott Gottlieb

Dear Dr. Gottlieb, The Abuse Deterrent Coalition (ADC) commends the U.S. Food and Drug Administration (FDA) for its focus on the nation’s opioid epidemic by recognizing the promise of abuse-deterrent formulation (ADF) opioids to discourage abuse and incorporating expanding access to thes...

ICER In Context

Click here to read  a short paper recently issued by the Abuse Deterrent Coalition that places the findings of ICER's report on abuse deterrent opioids in context. ...

ICER Presentation - Original Model Assumptions and Accompanying Outputs

We have received inquiries from some as to the substance of the initial ICER presentation (with their original model assumptions and the accompanying outputs). The attached is the February 22nd ICER presentation as the AD Coalition received it. Click here to access the presentation...

Report: Abuse-deterrent opioids too pricey for limited benefits

By Brett Norman An influential independent review board is casting new doubts on efforts supported by FDA and many lawmakers to push chronic pain treatment toward costly versions of opioids that are more difficult to abuse. The Institute for Clinical and Economic Review found that the adde...

White House opioid commission releases draft report

The President's Commission on Combating Drug Addiction and the Opioid Crisis issued a preliminary report on Monday stating that its “first and most urgent recommendation” is for the president to “declare a national emergency under either the Public Health Service Act or the Staffor...

Abuse-Deterrent Opioids and the Post-Approval Valley of Death

Although 10 new opioid products with abuse-deterrent formulations (ADF) have received regulatory approval in the United States, lack of willingness by insurers to reimburse patients for their use is seen as a primary challenge limiting ADF uptake, according to the Tufts Center for the Study of Drug ...